A comparative study of respiratory syncytial virus RSV prophylaxis in premature infants within the Canadian Registry of Palivizumab CARESSReport as inadecuate




A comparative study of respiratory syncytial virus RSV prophylaxis in premature infants within the Canadian Registry of Palivizumab CARESS - Download this document for free, or read online. Document in PDF available to download.

European Journal of Clinical Microbiology and Infectious Diseases

, Volume 31, Issue 10, pp 2703–2711

First Online: 01 May 2012Received: 17 February 2012Accepted: 27 March 2012

Abstract

We examined the dosing regimens, compliance, and outcomes of premature infants who received palivizumab within the Canadian Registry of Palivizumab CARESS. Infants receiving ≥1 dose of palivizumab during the 2006–2011 respiratory syncytial virus RSV seasons were recruited across 30 sites. Respiratory illness events were captured monthly. Infants ≤32 completed weeks gestational age GA Group 1 were compared to 33–35 completed weeks GA infants Group 2 following prophylaxis. In total, 6,654 patients were analyzed Group 1, n = 5,183; Group 2, n = 1,471. The mean GA was 29.9 ± 2.9 versus 34.2 ± 2.2 weeks for Groups 1 and 2, respectively. Group differences were significant all p-values <0.05 for the following: proportion of males, Caucasians, siblings, multiple births, maternal smoking, smoking during pregnancy, household smokers, >5 household individuals, birth weight, and enrolment age. Overall, infants received 92.6 % of expected injections. Group 1 received significantly more injections, but a greater proportion of Group 2 received injections within recommended intervals. The hospitalization rates were similar for Groups 1 and 2 for respiratory illness 4.7 % vs. 3.7 %, p = 0.1 and RSV 1.5 % vs. 1.4 %, p = 0.3. Neither the time to first respiratory illness hazard ratio = 0.9, 95 % confidence interval CI 0.7–1.2, p = 0.5 nor to first RSV hospitalization hazard ratio = 1.3, 95 % CI 0.8–2.2, p = 0.3 were different. Compliance with RSV prophylaxis is high. Despite the higher number of palivizumab doses in infants ≤32 completed weeks GA, the two groups’ respiratory illness and RSV-positive hospitalization rates were similar.

The CARESS Investigators corporate author: U. Allen, G. Bacheyie, A. Bayliss, C. Bjornson, M. Blayney, A.-M. Canakis, R. Canning, G. Caouette, K. Chang, L. Chang, A. Chiu, B. DiGravio, J.P. Doray, M.E. Dumas, V. Ho, C. Hui, F. Jagdis, M. Lebel, D. Lee, C. Majaesic, I. Margolis, M. Mitchell, K. O’Brien, C. Ojah, A. Papageorgiou, J. Popovich, K. Sankaran, B. Simmons, D. Stinson.

Download fulltext PDF



Author: B. Paes - I. Mitchell - A. Li - K. L. Lanctôt - The CARESS Investigators

Source: https://link.springer.com/







Related documents